Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 4
2007 pubmed

Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis.

Frutos. Miriam García-San MG; Cacicedo. Lucinda L; Fernández. Carolina C; Vicent. David D; Velasco. Beatriz B; Zapatero. Helena H; Sánchez-Franco. Franco F

Key Findings

  • Aging rats show a sharp drop in hypothalamic GHRH and somatostatin, which likely drives the GH decline.
  • GHRP‑6 treatment in old rats restored GH and IGF‑1 secretion to youthful levels and partially normalized pituitary GH markers.
  • The GH‑boosting effect of ghrelin (and by extension GHRP‑6) depends on the presence of hypothalamic cells, indicating a central mechanism.

Practical Outcomes

  • For biohackers, GHRP‑6 appears promising as a way to rejuvenate the GH/IGF‑1 axis in older adults, but human studies are still needed. If experimenting, start with low, intermittent doses, monitor IGF‑1 and GH levels, and watch for side effects. Combine with lifestyle factors that support hypothalamic health (sleep, nutrition) for potentially better results.

Summary

In older rats, the growth hormone secretagogue GHRP‑6 brought back the levels of growth hormone (GH) and IGF‑1 to those seen in young adults, suggesting that this peptide can counteract the natural age‑related drop in the GH/IGF‑1 system.

Abstract

Growth hormone (GH) secretion and serum insulin-like growth factor-I (IGF-I) decline with aging. This study addresses the role played by the hypothalamic regulators in the aging GH decline and investigates the mechanisms through which growth hormone secretagogues (GHS) activate GH secretion in the aging rats. Two groups of male Wistar rats were studied: young-adult (3 mo) and old (24 mo). Hypothalamic growth hormone-releasing hormone (GHRH) mRNA and immunoreactive (IR) GHRH dramatically decreased (P < 0.01 and P < 0.001) in the old rats, as did median eminence IR-GHRH. Decreases of hypothalamic IR-somatostatin (SS; P < 0.001) and SS mRNA (P < 0.01), and median eminence IR-SS were found in old rats as were GHS receptor and IGF-I mRNA (P < 0.01 and P < 0.05). Hypothalamic IGF-I receptor mRNA and protein were unmodified. Both young and old pituitary cells, cultured alone or cocultured with fetal hypothalamic cells, responded to ghrelin. Only in the presence of fetal hypothalamic cells did ghrelin elevate the age-related decrease of GH secretion to within normal adult range. In old rats, growth hormone-releasing peptide-6 returned the levels of GH and IGF-I secretion and liver IGF-I mRNA, and partially restored the lower pituitary IR-GH and GH mRNA levels to those of young untreated rats. These results suggest that the aging GH decline may result from decreased GHRH function rather than from increased SS action. The reduction of hypothalamic GHS-R gene expression might impair the action of ghrelin on GH release. The role of IGF-I is not altered. The aging GH/IGF-I axis decline could be rejuvenated by GHS treatment.

Study Information

Provider

pubmed

Year

2007

Date

2007-08-07T00:00:00.000Z

DOI

10.1152/ajpendo.00236.2007